Menu Search
Equities

Telo Genomics Corp

3D0A:DEU

Telo Genomics Corp

Actions
  • Price (EUR)0.096
  • Today's Change-0.004 / -4.00%
  • Shares traded1.00k
  • 1 Year change-46.96%
  • Beta--
Data delayed at least 15 minutes, as of May 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-3.07m
  • Incorporated2011
  • Employees--
  • Location
    Telo Genomics CorpMars Centre, 101 College St Suite 200TORONTO M5G 1L7CanadaCAN
  • Phone+1 (416) 673-8487
  • Fax+1 (204) 582-0922
  • Websitehttps://www.telodx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.